ESR1 and breast cancer: The International Ki67 Working Group (IKWG) suggests using cut-offs of ≤5 % for low proliferation and ≥30 % for high proliferation for estimating prognosis in ER+/HER2- T1-T2, N0-N1 breast cancer[17].